HC Wainwright Decreases Earnings Estimates for Ekso Bionics

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for shares of Ekso Bionics in a report issued on Tuesday, October 29th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.48) per share for the year, down from their previous estimate of ($0.42). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q4 2024 earnings at ($0.06) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.04) EPS and Q4 2025 earnings at ($0.02) EPS.

Several other equities analysts also recently commented on the stock. Lake Street Capital dropped their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com started coverage on shares of Ekso Bionics in a report on Saturday, October 26th. They issued a “hold” rating for the company.

Ekso Bionics Stock Up 3.6 %

Ekso Bionics stock opened at $0.89 on Thursday. Ekso Bionics has a fifty-two week low of $0.83 and a fifty-two week high of $3.13. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.77 and a current ratio of 2.81. The firm has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.15. The company has a market capitalization of $19.51 million, a PE ratio of -1.34 and a beta of 1.45.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same period last year, the business earned ($0.24) earnings per share.

Institutional Trading of Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.